

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Levothyroxine Formulation

Other means of identification : Leventa (A010426)

1.2 Relevant identified uses of the substance or mixture and uses advised againstUse of the Sub-
stance/Mixture : Veterinary productRecommended restrictions
on use : Not applicable**1.3 Details of the supplier of the safety data sheet**Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com**1.4 Emergency telephone number**

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Flammable liquids, Category 3

Reproductive toxicity, Category 2

Specific target organ toxicity - repeated
exposure, Category 1

H226: Flammable liquid and vapour.

H361: Suspected of damaging fertility or the un-
born child.H372: Causes damage to organs through pro-
longed or repeated exposure.**2.2 Label elements****Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Danger

Levothyroxine Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 1130666-00020 Date of last issue: 03.12.2024
Date of first issue: 30.11.2016

Hazard statements : H226 Flammable liquid and vapour.
H361 Suspected of damaging fertility or the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P233 Keep container tightly closed.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:
levothyroxine sodium

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Vapours may form explosive mixture with air.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Ethanol#	64-17-5 200-578-6 603-002-00-5	Flam. Liq. 2; H225 Eye Irrit. 2; H319	>= 10 - < 20
levothyroxine sodium	55-03-8 200-221-4	Acute Tox. 2; H300 Repr. 2; H361 STOT RE 1; H372 (Thyroid, Cardio-vascular system, Central nervous system)	>= 0,1 - < 1

For explanation of abbreviations see section 16.
#: Voluntarily-disclosed substance

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

SECTION 4: First aid measures**4.1 Description of first aid measures**

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|---|
| Risks | : | Suspected of damaging fertility or the unborn child.
Causes damage to organs through prolonged or repeated exposure. |
|-------|---|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|
-

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- | | | |
|--------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | High volume water jet |

5.2 Special hazards arising from the substance or mixture

- | | | |
|-------------------------------|---|--|
| Specific hazards during fire- | : | Do not use a solid water stream as it may scatter and spread |
|-------------------------------|---|--|

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

fighting

fire.
Flash back possible over considerable distance.
Vapours may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Remove all sources of ignition.
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Non-sparking tools should be used.
Soak up with inert absorbent material.
Suppress (knock down) gases/vapours/mists with a water spray jet.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.
Use explosion-proof electrical, ventilating and lighting equipment. |
| Advice on safe handling | : | Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Non-sparking tools should be used.
Keep container tightly closed.
Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. Keep away from heat and sources of ignition. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Flammable solids
Pyrophoric liquids
Pyrophoric solids
Self-heating substances and mixtures
Substances and mixtures, which in contact with water, emit |

Levothyroxine Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 1130666-00020 Date of last issue: 03.12.2024
 Date of first issue: 30.11.2016

flammable gases
 Explosives
 Gases
 Very acutely toxic substances and mixtures

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ethanol	64-17-5	OEL- RL STEL/C	2.000 ppm	ZA OEL
Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents				
levothyroxine sodium	55-03-8	TWA	0.1 µg/m ³ (OEB 5)	Internal
		Wipe limit	1 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Ethanol	Workers	Inhalation	Long-term systemic effects	380 mg/m ³
	Workers	Skin contact	Long-term systemic effects	267 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	114 mg/m ³

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Ethanol	Fresh water	0,96 mg/l
	Freshwater - intermittent	2,75 mg/l
	Marine water	0,79 mg/l
	Sewage treatment plant	580 mg/l
	Fresh water sediment	3,6 mg/kg dry weight (d.w.)
	Marine sediment	2,9 mg/kg dry weight (d.w.)
	Soil	0,63 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	380 mg/kg food

8.2 Exposure controls

Engineering measures

Use explosion-proof electrical, ventilating and lighting equipment.
 The information below is intended for larger pilot/commercial-scale operations and manufacturing.
 For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving. Take note that the product is flammable, which may impact the selection of hand protection.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	Aqueous solution
Colour	:	colourless
Odour	:	slight
Odour Threshold	:	No data available
pH	:	9,7 - 10,7
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	44 °C

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1,05 g/cm ³
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Particle size	:	Not applicable
---------------	---	----------------

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Flammable liquid and vapour. Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Conditions to avoid : Heat, flames and sparks.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents
Acids

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Ethanol:**

Acute oral toxicity : LD50 (Rat): 10.470 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat, male): 116,9 mg/l
Exposure time: 4 h
Test atmosphere: vapour

Acute dermal toxicity : LD50 (Rabbit): > 15.800 mg/kg

levothyroxine sodium:

Acute oral toxicity : TDLo (Humans): 10 mg/kg
TDLo (Dog): 10 mg/kg
LD50 (Rat): > 1.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 50 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 20 mg/kg
Application Route: Intraperitoneal
LD50 (Rat): 50 mg/kg
Application Route: Subcutaneous

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Skin corrosion/irritation

|| Not classified based on available information.

Components:**Ethanol:**

Species	: Rabbit
Method	: OECD Test Guideline 404
Result	: No skin irritation

Serious eye damage/eye irritation

|| Not classified based on available information.

Components:**Ethanol:**

Species	: Rabbit
Method	: OECD Test Guideline 405
Result	: Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation**Skin sensitisation**

|| Not classified based on available information.

Respiratory sensitisation

|| Not classified based on available information.

Components:**Ethanol:**

Test Type	: Mouse ear swelling test (MEST)
Exposure routes	: Skin contact
Species	: Mouse
Result	: negative

Germ cell mutagenicity

|| Not classified based on available information.

Components:**Ethanol:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Method: OECD Test Guideline 471
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Method: OECD Test Guideline 476
	Result: negative
	Test Type: Chromosome aberration test in vitro
	Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo)

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

cytogenetic assay)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging fertility or the unborn child.

Components:**Ethanol:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
Result: negative

levothyroxine sodium:

Effects on foetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0,25 mg/kg body weight

Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 3 mg/kg body weight

Test Type: Development
Species: Rabbit
Result: No teratogenic effects

Test Type: Development
Species: Guinea pig
Result: No teratogenic effects

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:**levothyroxine sodium:**

Target Organs : Thyroid, Cardio-vascular system, Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Repeated dose toxicity**Components:****Ethanol:**

Species	: Rat
NOAEL	: 1.730 mg/kg
LOAEL	: 3.200 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****levothyroxine sodium:**

Ingestion	: Target Organs: Thyroid Target Organs: Cardio-vascular system Target Organs: Central nervous system Symptoms: Palpitation, hypotension, Tremors, Headache, increase in appetite, Sweating, Vomiting, Diarrhoea, Fever, nervousness, weight loss
-----------	---

SECTION 12: Ecological information**12.1 Toxicity****Components:****Ethanol:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): 14.200 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Ceriodaphnia dubia (water flea)): 5.012 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l Exposure time: 72 h EC10 (Chlorella vulgaris (Fresh water algae)): 11,5 mg/l Exposure time: 72 h
Toxicity to microorganisms	: EC50 (Protozoa): 5.800 mg/l Exposure time: 4 h
Toxicity to fish (Chronic toxicity)	: NOEC: >= 79 mg/l Exposure time: 100 d Species: Oryzias latipes (Japanese medaka)
Toxicity to daphnia and other aquatic invertebrates (Chronic)	: NOEC: 9,6 mg/l Exposure time: 9 d

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

|||ic toxicity)

Species: Daphnia magna (Water flea)

12.2 Persistence and degradability

Components:Ethanol:

|||Biodegradability

: Result: Readily biodegradable.
Biodegradation: 84 %
Exposure time: 20 d

12.3 Bioaccumulative potential

Components:Ethanol:|||Partition coefficient: n-
octanol/water

: log Pow: -0,35

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:Endocrine disrupting poten-
tial

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Do not dispose of waste into sewer.

Contaminated packaging

: Empty containers should be taken to an approved waste handling site for recycling or disposal.
Empty containers retain residue and can be dangerous.
Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

of ignition. They may explode and cause injury and/or death.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN	:	UN 1170 Not permitted for transport
ADR	:	UN 1170 Not permitted for transport
RID	:	UN 1170 Not permitted for transport
IMDG	:	UN 1170
IATA	:	UN 1170

14.2 UN proper shipping name

ADN	:	ETHANOL Not permitted for transport
ADR	:	ETHANOL Not permitted for transport
RID	:	ETHANOL Not permitted for transport
IMDG	:	ETHANOL
IATA	:	Ethanol

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	3
ADR	:	3
RID	:	3
IMDG	:	3
IATA	:	3

14.4 Packing group

ADN	:	Not permitted for transport
ADR	:	Not permitted for transport
RID	:	Not permitted for transport
IMDG	:	
Packing group	:	III
Labels	:	3
EmS Code	:	F-E, S-D
IATA (Cargo)	:	
Packing instruction (cargo aircraft)	:	366

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Packing instruction (LQ)	: Y344
Packing group	: III
Labels	: Flammable Liquids

IATA (Passenger)

Packing instruction (passenger aircraft)	: 355
Packing instruction (LQ)	: Y344
Packing group	: III
Labels	: Flammable Liquids

14.5 Environmental hazards**ADN**

Environmentally hazardous	: no
---------------------------	------

ADR

Environmentally hazardous	: no
---------------------------	------

RID

Environmentally hazardous	: no
---------------------------	------

IMDG

Marine pollutant	: no
------------------	------

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks	: Not applicable for product as supplied.
---------	---

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	--

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Full text of H-Statements

H225	: Highly flammable liquid and vapour.
H300	: Fatal if swallowed.
H319	: Causes serious eye irritation.
H361	: Suspected of damaging fertility or the unborn child.
H372	: Causes damage to organs through prolonged or repeated exposure.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Eye Irrit.	: Eye irritation
Flam. Liq.	: Flammable liquids
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
ZA OEL	: South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits
ZA OEL / OEL- RL STEL/C	: Occupational Exposure Limit Restricted limit - Short term occupational exposure limits / ceiling limits

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data	: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-
---	---

Levothyroxine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
5.0	14.04.2025	1130666-00020	Date of first issue: 30.11.2016

Sheet cy, <http://echa.europa.eu/>**Classification of the mixture:**

Flam. Liq. 3	H226
Repr. 2	H361
STOT RE 1	H372

Classification procedure:

Based on product data or assessment
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN